Singapore-based Harvest Integrated Research Organization, or HiRO, has expanded its global footprint with the acquisition of Courante Oncology, a Minnesota-based CRO that specializes in oncology.
The deal represents a big step for HiRO in establishing itself as a global player, the company said in an Aug. 31 press release. Financial terms of the deal weren’t disclosed.
Courante, which has been in the drug development arena for more than 25 years, has experience in phase 1-3 clinical trials, including initial feasibility studies, protocol development, site monitoring and closeout visits.
Consolidation within the CRO industry continues unabated. In recent weeks, RQM+ acquired German CRO Kottmann, Sygnature Discovery purchased NuChem Sciences, Frontage Labs picked up Nucro-Technics and Kohlberg & Co. bought Worldwide Clinical Trials.